Discussion stirs around Tesaro, Inc. (NASDAQ:TSRO) this week; here is what analysts are saying.

November 10, 2018 - By Jason Grubb

Tesaro, Inc. (NASDAQ:TSRO) LogoInvestors sentiment decreased to 0.93 in Q2 2018. Its down 0.21, from 1.14 in 2018Q1. It worsened, as 59 investors sold Tesaro, Inc. shares while 44 reduced holdings. 29 funds opened positions while 67 raised stakes. 58.58 million shares or 3.28% less from 60.57 million shares in 2018Q1 were reported.
First Republic Inv has invested 0% in Tesaro, Inc. (NASDAQ:TSRO). Bank & Trust Of Montreal Can owns 9,515 shares. Macquarie Gru Ltd owns 0.02% invested in Tesaro, Inc. (NASDAQ:TSRO) for 323,748 shares. Dimensional Fund Advisors Limited Partnership reported 5,877 shares. Blackrock Inc holds 4.22 million shares or 0.01% of its portfolio. 11,000 are owned by Nj State Employees Deferred Compensation Plan. 2.06 million are owned by State Street. Tekla Mngmt Lc accumulated 94,970 shares or 0.16% of the stock. Pnc Fin Service Gru Inc holds 1,036 shares or 0% of its portfolio. Rhumbline Advisers invested 0% of its portfolio in Tesaro, Inc. (NASDAQ:TSRO). Bb Biotech Ag holds 3.12% of its portfolio in Tesaro, Inc. (NASDAQ:TSRO) for 2.43 million shares. Glob X Mngmt Co Ltd stated it has 0% in Tesaro, Inc. (NASDAQ:TSRO). Federated Inc Pa reported 182,605 shares. Renaissance Lc holds 0.01% of its portfolio in Tesaro, Inc. (NASDAQ:TSRO) for 186,500 shares. Elk Creek Ptnrs Ltd reported 191,815 shares.

Since June 12, 2018, it had 0 insider buys, and 2 insider sales for $310,256 activity. The insider Alleva Lawrence M sold $307,920.

Tesaro, Inc. (NASDAQ:TSRO) Ratings Coverage

Among 5 analysts covering Tesaro (NASDAQ:TSRO), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Tesaro had 10 analyst reports since May 31, 2018 according to SRatingsIntel. Cantor Fitzgerald maintained Tesaro, Inc. (NASDAQ:TSRO) on Monday, October 22 with “Overweight” rating. On Friday, November 2 the stock rating was maintained by Bank of America with “Neutral”. The stock has “Overweight” rating by Barclays Capital on Monday, August 6. The firm has “Neutral” rating by Bank of America given on Tuesday, September 11. Barclays Capital upgraded it to “Buy” rating and $6000 target in Wednesday, June 27 report. The stock has “Neutral” rating by Bank of America on Monday, August 6. Citigroup maintained the shares of TSRO in report on Thursday, May 31 with “Buy” rating. As per Wednesday, August 29, the company rating was maintained by Citigroup. Below is a list of Tesaro, Inc. (NASDAQ:TSRO) latest ratings and price target changes.

02/11/2018 Broker: Bank of America Old Rating: Neutral New Rating: Neutral Old Target: $38 New Target: $39 Maintain
22/10/2018 Broker: Cantor Fitzgerald Old Rating: Overweight New Rating: Overweight Old Target: $57 New Target: $68 Maintain
01/10/2018 Broker: Cantor Fitzgerald Rating: Overweight New Target: $57 Initiates Coverage On
25/09/2018 Broker: Leerink Swann Rating: Outperform New Target: $48 Initiates Coverage On
11/09/2018 Broker: Bank of America Old Rating: Neutral New Rating: Neutral Old Target: $35 New Target: $38 Maintain
29/08/2018 Broker: Citigroup Old Rating: Buy New Rating: Buy Old Target: $100 New Target: $85 Maintain
06/08/2018 Broker: Barclays Capital Old Rating: Overweight New Rating: Overweight Old Target: $60 New Target: $56 Maintain
06/08/2018 Broker: Bank of America Old Rating: Buy New Rating: Neutral Downgrade
27/06/2018 Broker: Barclays Capital Rating: Buy New Target: $60.0000 Upgrade
31/05/2018 Broker: Citigroup Rating: Buy New Target: $100.0000 Maintain

The stock decreased 18.80% or $5.81 during the last trading session, reaching $25.1. About 3.88 million shares traded or 125.64% up from the average. Tesaro, Inc. (NASDAQ:TSRO) has declined 70.32% since November 10, 2017 and is downtrending. It has underperformed by 85.94% the S&P500.

Tesaro, Inc., an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. The company has market cap of $1.38 billion. It markets Rolapitant, a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting under the VARUBI brand name. It currently has negative earnings. The firm is also developing Niraparib, an orally active and potent poly polymerase inhibitor, which is in various clinical trials to treat ovarian or breast cancers.

More notable recent Tesaro, Inc. (NASDAQ:TSRO) news were published by: Globenewswire.com which released: “TESARO Announces Data Presentations at ESMO 2018 Congress” on October 20, 2018, also Seekingalpha.com with their article: “Tesaro Q3 Zejula sales up 60%; shares up 4% after hours” published on November 01, 2018, Fool.com published: “Here’s Why Tesaro Inc. Dropped 13.8% Today” on October 24, 2018. More interesting news about Tesaro, Inc. (NASDAQ:TSRO) were released by: Seekingalpha.com and their article: “Tesaro down 19% on disappointing early-stage data on cancer combo” published on November 09, 2018 as well as Benzinga.com‘s news article titled: “The Daily Biotech Pulse: SITC Presentations Pick Up Pace, Sandoz’ Voluntary Recall” with publication date: November 09, 2018.

Tesaro, Inc. (NASDAQ:TSRO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: